The landscape of mergers and acquisitions in the life sciences sector is evolving rapidly, driven by an array of economic forces and emerging technologies. As we move through 2026, the insights from Subin Baral, the global life sciences deals leader at EY, shed light on the current dynamics shaping this critical industry.
M&A Acceleration in 2025
The EY’s recent report reveals a remarkable 81% increase in M&A spending in 2025, reaching a staggering $240 billion. Interestingly, this surge occurred alongside a 12% decline in the volume of deals, indicating a shift in strategy among companies. Organizations are increasingly pursuing de-risked assets that are either on the market or nearing commercialization, willing to pay substantial premiums for these opportunities. The average deal size has seen a notable increase of 107%, highlighting the fierce competition for attractive assets, particularly in sectors like GLP-1 and anti-obesity treatments, oncology, and central nervous system (CNS) therapies.
The Medtech sector has particularly outperformed biopharma, with investment growth soaring to 116% compared to 65% for biopharma. The dominance of Medtech is underscored by the fact that the three largest deals of the year all originated within this sector, emphasizing a robust focus on high-growth potential across the life sciences.
Pipeline Pressures and Growth Gaps
Despite the escalating investment, the industry faces significant challenges. A wave of patent expirations is looming, necessitating the replacement of lost revenues. Analysis suggests that leading biopharma companies are currently unprepared to fill this gap, facing a projected shortfall of over $370 billion by 2032. This growth gap illustrates a concerning trend: the leading firms lack sufficient pipeline assets to sustain their projected growth.
Moreover, skepticism surrounding the quality of existing pipelines and the ability of companies to execute their strategies further complicates the landscape. With few high-quality, low-risk assets available, the competition for these coveted deals intensifies, leading to higher costs and greater pressure on companies to engage in strategic acquisitions.
The Role of China in Biopharma Innovation
China has emerged as a pivotal player in the biopharma innovation space. The country’s robust R&D capabilities, coupled with expedited data collection and shortened approval timelines, have made it an attractive destination for global partnerships. In 2025, collaborations between multinational biopharma firms and domestic Chinese biotechs accounted for over one-third of the “biobucks” spent on alliances, a staggering increase from less than 1% ten years prior.
This trend indicates a shift towards alliances as a key investment strategy, with a total potential spend of approximately $234 billion on alliance deals. These partnerships not only facilitate access to innovative technologies, including next-generation oncology treatments and AI solutions, but also lower the upfront costs associated with investing in new developments.
Future Trends in M&A
Looking ahead, the M&A landscape is poised for continued activity as companies grapple with existing growth gaps and the relentless drive for innovation. Two prominent trends are emerging. First, life sciences companies are becoming increasingly reliant on dealmaking as a growth strategy. Analysis indicates that up to two-thirds of revenue for leading biopharmas comes from strategic acquisitions. Companies that engage in diverse dealmaking outperform their less active counterparts.
Second, while M&A remains vital, the complexity of successful execution cannot be overlooked. Current estimates suggest that as many as 68% of deals fail to meet their projected growth targets. This reality is pushing companies to prioritize flawless execution in their M&A strategies, often leveraging AI tools to identify potential targets and streamline integration processes.
Understanding Industry Firepower
The life sciences industry boasts an impressive $2.1 trillion in firepower, with biopharma accounting for approximately $1.6 trillion and Medtech the remainder. This substantial financial capacity positions the industry to pursue strategic initiatives aggressively. However, this firepower is not uniformly distributed. Some companies hold significant reserves, while others face constraints in their dealmaking capabilities.
Recent surges in market capitalization, particularly following investor enthusiasm for GLP-1 drugs, have also contributed to the overall financial landscape. While the $2.1 trillion figure is striking, it does not imply that all companies are equally prepared for aggressive dealmaking in 2026. For those with the necessary financial resources and growth gaps, however, the potential for M&A activity is substantial.
Key Takeaways
- M&A activity in life sciences surged by 81% in 2025, with companies seeking high-quality, near-market assets.
-
The Medtech sector outpaced biopharma, indicating a preference for high-growth opportunities.
-
A looming growth gap of over $370 billion by 2032 highlights the urgent need for pipeline replenishment among leading biopharma firms.
-
China is becoming a strategic hub for biopharma innovation, with increasing investment in partnerships.
-
Future M&A strategies will likely focus on flawless execution, leveraging AI to enhance target identification and integration.
In summary, the life sciences M&A landscape is at a pivotal moment, characterized by fierce competition, strategic alliances, and evolving challenges. As companies navigate these complexities, a focus on innovation and strategic partnerships will be essential for sustained growth and success.
Read more → www.pharmexec.com